Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
Open Access
- 16 August 2021
- journal article
- case report
- Published by Wiley in Clinical Case Reports
- Vol. 9 (8) , e04625
Abstract
Raynaud's phenomenon is a rare side effect of CGRP monoclonal antibodies. These molecular treatments are a relatively new class of drugs for the prevention of migraine. It is likely that we will see this side effect more often in the future. Patients with a background of Raynaud's phenomenon may experience worsening of their symptoms if started on these treatments.Keywords
All Related Versions
This publication has 7 references indexed in Scilit:
- Raynaud's phenomenonBest Practice & Research Clinical Rheumatology, 2020
- Raynaud's Phenomenon Associated With Calcitonin Gene‐Related Peptide Monoclonal Antibody AntagonistsHeadache: The Journal of Head and Face Pain, 2019
- Innovations in the Assessment of Primary and Secondary Raynaud’s PhenomenonFrontiers in Pharmacology, 2019
- CGRP as the target of new migraine therapies — successful translation from bench to clinicNature Reviews Neurology, 2018
- Chronic Migraine Prevalence, Disability, and Sociodemographic Factors: Results From the American Migraine Prevalence and Prevention StudyHeadache: The Journal of Head and Face Pain, 2012
- Calcitonin Gene‐Related Peptide (CGRP) and MigraineHeadache: The Journal of Head and Face Pain, 2006
- CGRP-Receptor Antagonists — A Fresh Approach to Migraine Therapy?New England Journal of Medicine, 2004